Dermatología en Costa Rica

Wednesday, March 29, 2017

Nuevo y primer tratamiento aprobado para Cancer de Celulas de Merkel


First Merkel cell carcinoma treatment approved

The U.S. Food and Drug Administration has granted accelerated approval to EMD Serono's Bavencio (avelumab) to treat patients ages 12 and up with metastatic Merkel cell carcinoma, including patients who have not received chemotherapy. The PD-L-1 inhibitor was approved based on data from a single-arm trial of 88 patients with metastatic MCC who had been previously treated with at least one prior chemotherapy regimen, 33 percent of whom experienced complete or partial shrinkage of their tumors. The response lasted for more than six months in 86 percent of responding patients and more than 12 months in 45 percent of responding patients. The treatment can cause a number of side effects, may lead the immune system to attack healthy cells or organs, and carries the risk of infusion-related reactions. 

Biologics and targeted therapies are helping dermatologists treat many skin conditions more effectively than ever before — and more are in the pipeline. Read more about conditions that may see new treatment options in the near future in Dermatology World


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Nuevo medicamento parq dermatitis atopica aprobado por la FDA.

Injectable Dupilumab Approved for Eczema

By Kelly Young

Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM

The FDA has approved dupilumab (Dupixent) to treat moderate-to-severe atopic dermatitis. It is indicated in adults whose eczema isn't well controlled by topical treatments or who can't use such treatments. The drug's list price is $37,000 per year, the New York Times reports.

The injectable human monoclonal antibody works by attaching to an inflammation-causing protein — interleukin-4 receptor alpha subunit. In two trials, skin clearance was more common among those given dupilumab than those who received placebo (37% vs. 10%) after 16 weeks of treatment.

Side effects include serious allergic reactions, conjunctivitis, and keratitis. Some of the more common adverse events include injection site reactions, cold sores around the mouth, and inflammation of the eye and eyelid.

FDA news release (Free)

New York Times story (Free)

Background: NEJM Journal Watch Dermatology coverage of dupilumab for atopic dermatitis (Your NEJM Journal Watch registration required)



Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Tuesday, March 28, 2017

Pacientes con Dermatitis Atópica presentan mayor riesgo de infecciones sistémicas.

Published in Dermatology

Journal Scan / Research · March 27, 2017

Increased Risk of Cutaneous and Systemic Infections in Atopic Dermatitis

Journal of Investigative Dermatology

TAKE-HOME MESSAGE

Atopic dermatitis (AD, also known as atopic eczema or eczema), is characterized by skin barrier and immunologic dysfunction. Viral and bacterial super-infection of cutaneous lesions including eczema herpeticum and staphylococcus aureus in patients with severe disease is well documented (Ong and Leung, 2016, Weidinger and Novak, 2016). Whether the general population of patients with AD has an increased risk of these and other types of infections due to an impaired skin barrier and/or immunologic dysfunction is unclear.

Increased Risk of Cutaneous and Systemic Infections in Atopic Dermatitis—A Cohort Study
J Invest Dermatol 2017 Feb 12;[EPub Ahead of Print], SM Langan, K Abuabara, SE Henrickson, O Hoffstad, DJ Margolis 

Más crio, para las queratosis actinicas en la Cara!

Published in Dermatology

Journal Scan / Research · March 27, 2017

Actinic Keratosis Cleared With Aggressive Freezing Techniques

Dermatologic Surgery

TAKE-HOME MESSAGE

BACKGROUND

Cryosurgery is the most commonly used method to treat actinic keratosis (AK). Cryosurgical methods are not standardized.

OBJECTIVE

To examine differences in the spray techniques used for liquid nitrogen cryosurgery when treating AKs of the head, and the effect of these variations in technique on rates of complete clearance of AKs.

MATERIALS AND METHODS

Patients were those from the FIELD-1 study, who received cryosurgery as per the investigators' usual practice to all AKs. This was followed by topical treatment with either vehicle gel or ingenol mebutate gel, 0.015%, after 3 weeks. The investigator recorded the average duration of cryosurgery spray used, the number of freeze-thaw cycles, and the distance from the tip of the spray device to the AK. Clearance rates were determined at Week 11.

RESULTS

Less-aggressive freezing techniques were used for AKs on the face than for those on the scalp. However, higher rates of complete clearance on the face and scalp were associated with more-aggressive freezing techniques.

CONCLUSION

Patients with AKs on the face receive less-aggressive cryosurgery than do patients with AKs on the scalp.


Variables in Cryosurgery Technique Associated With Clearance of Actinic Keratosis
Dermatol Surg 2017 Mar 01;43(3)424-430, B Berman, AQ Shabbir, T MacNeil, KM Knudsen 

Thursday, March 23, 2017

Confirman que la isotretinoina no se asocia a depresión.



Journal Scan / Research · March 22, 2017

Isotretinoin Treatment for Acne and Risk of Depression

Journal of the American Academy of Dermatology

TAKE-HOME MESSAGE

Journal of the American Academy of Dermatology
Isotretinoin Treatment for Acne and Risk of Depression: A Systematic Review and Meta-Analysis
J Am Acad Dermatol 2017 Mar 10;[EPub Ahead of Print], YC Huang, YC Cheng 


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Wednesday, March 22, 2017

Plasma rico en plaquetas impresiona ser efectivo en Alopecia Androgenetica


Journal Scan / Research · March 21, 2017

The Effect of Plasma Rich in Growth Factors on Androgenic Alopecia

Dermatologic Surgery

TAKE-HOME MESSAGE


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Recomwndaciones para prevencion de onicomicosis.

Avoid Unsightly Fungal Toenail Infections

Yes, you really do need to wear flip flops in the gym shower, dermatologist says

TUESDAY, March 21, 2017 (HealthDay News) -- Fungal nail infections, though unsightly, are generally painless and can often be prevented, a skin and nail specialist says.

"Fungal nail infections are common and tend to run in families because of an inherited tendency, although not everyone is susceptible," Dr. Joshua Zeichner said in an American Academy of Dermatology news release. 

"Since fungal nail infections are contagious, it's important to take precautions to reduce your risk of getting an infection," Zeichner added. He's an assistant professor of dermatology at the Icahn School of Medicine at Mount Sinai in New York City.

Signs that you've picked up a fungus include yellow or brown nails. The nail may also lift off the nail bed, or split or crumble.

So what can you do to keep this icky problem at bay?

The first step is keeping your toenails trimmed short. This helps prevent debris from building up under the nails and minimizes the risk of nail injuries. Cut nails straight across to keep them strong and avoid ingrown toenails, Zeichner advised.

In addition, always wear proper-fitting shoes. The tips of your shoes shouldn't touch your toenails. It's also a good idea to alternate your shoes each day so they can air out before you wear them again.

Breathable footwear is best, because fungus thrives in warm, moist areas, such as hot, sweaty shoes. Wear sandals whenever you can. If you have to wear socks, choose ones that wick moisture away from your skin, Zeichner said.

Put antifungal sprays or powders in your shoes and on your socks before wearing them in order to control sweat that can lead to fungal infections. Doing so is especially important in hot weather or before a workout, he noted.

Don't go barefoot in public places, such as pools and locker rooms. Zeichner recommends wearing shower shoes or flip flops to protect against fungus on the floor that can cause athlete's foot, ringworm and other skin conditions.

Never wear other people's shoes or share nail clippers and files. If you go to a nail salon, check that staff sanitize tools and thoroughly disinfect footbaths before each use, or use your own footbath. If the salon does not appear clean, go to another one, Zeichner said.

More information

The U.S. Centers for Disease Control and Prevention has more on fungal diseases.

SOURCE: American Academy of Dermatology, news release, March 14, 2017


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Medicamento cambia curso de psoriasis...

Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis

  • New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1]
      
  • Patients with longer disease duration before treatment with Cosentyx were more likely to relapse, highlighting the potential importance of early treatment with Cosentyx[1]
      
  • To further investigate disease modification, Novartis has initiated the STEPIn trial, evaluating Cosentyx in patients with early onset of moderate-to-severe psoriasis[2]

The digital press release with multimedia content can be accessed here:

 

Basel, March 21, 2017 Novartis today announced new data suggesting, for the first time, that Cosentyx® (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance[1]. Cosentyx is the first and only IL-17A inhibitor to have reported this potential of disease modification. These data were presented at the 13th Annual Maui Derm for Dermatologists 2017, Maui, Hawaii at which Novartis presented 14 abstracts.

Following one year of treatment with Cosentyx, patients were randomized to either continuous treatment or treatment cessation until relapse. Patients with continuous treatment maintained their high level of response. Among the patients that discontinued treatment, 21% of psoriasis patients maintained skin clearance for up to one year without treatment and 10% maintained skin clearance after two years without treatment[1]. Patients with longer disease duration were more likely to relapse, suggesting that early intervention increases the chance of remaining relapse free[1].

Previous data has shown that Cosentyx, a fully human, specific inhibitor of the IL-17A cytokine, delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in up to 80% of patients out to four years[3],[4].

"These results suggest that Cosentyx may go beyond simply treating symptoms and could actually modify the course of psoriasis, and highlights the need for further investigation into early intervention," said Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. "Being able to change the course of disease is the ultimate goal of treatment, which is why we are investing in the STEPIn trial to further understand the disease modifying ability of Cosentyx in psoriasis."

This is the first robust long-term data on psoriasis following treatment discontinuation. These data (from extension study A2302E1) show low scores on the Psoriasis Area Severity Index (PASI) were maintained after treatment discontinuation following one year on Cosentyx (PASI score of 2.9 after 1 year and 1.7 after 2 years off-drug, vs. 20.5 and 19.2 at Baseline)[1]. Additionally, of the 120 patients who were PASI 75 responders and switched to placebo at one year, 21% remained relapse-free after one year and 10% were relapse-free after two years off-treatment[1]. Patients who had a longer disease duration before Cosentyx treatment were more likely to relapse, highlighting the potential importance of early treatment[1]. To further investigate the disease modification potential of Cosentyx, Novartis has initiated the STEPIn trial to assess early intervention with Cosentyx in new-onset disease. The ambition is to identify a novel strategy of treating patients with new-onset moderate-to-severe psoriasis, by providing evidence to inform the use of early treatment[2].

Cosentyx is the only IL-17A inhibitor approved in psoriasis, psoriatic arthritis and ankylosing spondylitis. 80,000 patients have been treated worldwide in the post-marketing setting[5].

About Cosentyx and interleukin-17A (IL-17A)
Launched in January 2015, Cosentyx is a targeted treatment that specifically inhibits the IL-17A cytokine. Cosentyx delivers long-lasting clear skin, with proven sustainability, safety out to four years and convenient once-monthly dosing in a patient-friendly auto injector[6]. 

Cosentyx is approved in more than 75 countries for the treatment of moderate-to-severe plaque psoriasis, which includes the European Union countries, Japan, Switzerland, Australia, the US and Canada. In Europe, Cosentyx is approved for the first-line systemic treatment of moderate-to-severe plaque psoriasis in adult patients[7]. In the US, Cosentyx is approved as a treatment for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy (light therapy)[8]. 

In addition, Cosentyx is the first IL-17A inhibitor approved in more than 65 countries for the treatment of active AS and PsA, which includes the European Union countries and the US. Cosentyx is also approved for the treatment of PsA and pustular psoriasis in Japan[5].

About A2302E1[1]
A2302E1 is an extension of pivotal phase 3 studies ERASURE and FIXTURE made up of a double-blind, placebo-controlled study of 120 psoriasis patients. After one year of Cosentyx treatment, patients who achieved a PASI 75 response were randomized to receive either Cosentyx 300mg or placebo. During the treatment withdrawal concomitant psoriasis medication was prohibited. Upon relapse placebo patients were retreated with Cosentyx. 

About STEPIn[2]
A randomized, multicenter study to evaluate the effect of secukinumab 300 mg s.c. administered during 52 weeks to patients suffering from new-onset moderate-to-severe plaque psoriasis as early intervention compared to standard of care treatment with narrow-band UVB. STEPIn aims to demonstrate the benefit of early secukinumab treatment with the ultimate goal of altering the natural course psoriasis with a reduced disease burden and need for treatment.

About psoriasis
Psoriasis is a common, non-contagious, autoimmune disease that affects more than 125 million people worldwide[9]. Plaque psoriasis is the most common form of the disease and appears as raised, red patches covered with a silvery white buildup of dead skin cells.

Psoriasis is not simply a cosmetic problem, but a persistent, chronic (long-lasting), and sometimes distressing disease, which can affect even the smallest aspects of people's lives on a daily basis. Up to 30% of patients with psoriasis have, or will develop, PsA[10]. PsA is a condition in which the joints are also affected, causing debilitating symptoms including pain, stiffness and irreversible joint damage[10],[11]. Psoriasis is also associated with other serious health conditions, such as diabetes, heart disease and depression[8].


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Friday, March 17, 2017

Psoriasis y tiroides

Los pacientea con psoriasis tienen mayor riesgo de Tiroiditis de Hashimoto.

Psoriasis, Hashimoto's Thyroiditis Link Found

Int J Dermatol; ePub 2017 Feb 19; Kiguradze, et al

A significant association existed for psoriasis and Hashimoto's thyroiditis (HT), even after adjusting for confounding variables that included gender, age, psoriatic arthropathy, and the use of systemic anti-psoriatic agents, a recent study found. Researchers searched 1 institution's electronic medical record data repository from January 2010 to December 2013. Patients were identified by ICD-9 codes for psoriasis and HT. They found:

  • Medical records for 856,615 individuals with documented encounters between January 1, 2010, and December 31, 2013, were detected.
  • A total of 9,654 had a diagnosis of psoriasis, and 1,745 had a diagnosis of HT.
  • Of these, 41 subjects were diagnosed with both conditions.
  • This association has broad clinical impact and deserves further attention with regard to patient care, clinical research, and developmental therapeutics.
Citation:

Kiguradze T, Bruins FM, Guido N, et al. Evidence for the association of Hashimoto's thyroiditis with psoriasis: A cross-sectional retrospective study. [Published online ahead of print February 19, 2017]. Int J Dermatol. doi:10.1111/ijd.13459.


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Primer estudio de MTX

Primer estudio randomizado sobre uso de metotrexate subcutaneo, mostrando PASI 75 en 45% de pacientes a 52 semanas en dosis de 22.5mg por semana.

Subcutaneous high-dose methotrexate controls psoriasis

Subcutaneous high-dose methotrexate can be safely initiated in people with moderate to severe psoriasis, and produces a rapid and sustained response, researchers found.

Although methotrexate is a first-line agent in moderate to severe psoriasis, and is considerably cheaper than biological agents, much remains unknown about its ideal dosage and route of administration.

Authors of a 2016 systematic reviewnoted that, despite the fact that methotrexate has been used for more than 50 years in psoriasis, high-quality trial evidence remains wanting (PLoS One 2016 May 11. doi: 10.1371/journal.pone.0153740). Recent, well-designed trials have compared methotrexate to biological drugs used in psoriasis rather than placebo. These studies also have used oral formulations of methotrexate, in a range of starting doses as low as 5 mg, rather than subcutaneous formulations.

Richard B. Warren, MD, of the University of Manchester, England, and his colleagues carried out the first double-blind, placebo-controlled study of a two-step dosing regimen of subcutaneous methotrexate in this population, in research published in the Feb. 4 issue of the Lancet (Lancet 2017;389[10068]:528-37).

In their 52-week, multicenter trial conducted across 13 study sites in Europe, Dr. Warren and his colleagues randomized 120 patients to subcutaneous methotrexate at a dose of 17.5 mg/week (n = 91) or sham injections (n = 29) for 16 weeks. Patients in the intervention arm who did not achieve at least 50% improvement on the baseline Psoriasis Area and Severity Index (PASI) score at 8 weeks were increased to 22.5 mg methotrexate per week; 31% received this dose increase.

The study's primary endpoint was reduction of the PASI score by 75% or more at 16 weeks, which 41% of the intervention arm achieved, compared with 10% of patients in the placebo arm (relative risk 3.93, P = .0026). After 16 weeks, all patients in the cohort were converted to open-label methotrexate for the remainder of the trial, following the same dosing schedule of between 17.5 and 22.5 mg, depending on response at 8 weeks after initiation.

At week 52, PASI 75 response rates were 45% in the methotrexate-methotrexate group and 34% in the placebo-methotrexate group. This compared favorably, the researchers wrote, with a previous study in which the PASI 75 response rate at week 52 was 24% with oral methotrexate at doses of up to 25 mg per week.

No serious adverse events were associated with methotrexate, although gastrointestinal problems (mostly nausea) and elevated liver enzymes were more common in patients receiving the treatment.

"Our findings encourage the use of subcutaneous methotrexate for treatment of psoriasis, and suggest long-term clinical outcomes better than previously reported for oral administration, although final confirmation will be needed in a direct head-to-head trial of subcutaneous versus oral dosing. Our findings might also help to guide future recommendations for the optimum dosing of methotrexate," the investigators wrote.

Medac Pharma funded the study. Dr. Warren and six of his coauthors disclosed financial relationships with multiple pharmaceutical firms, including the study sponsor, while three coauthors declared no financial conflicts of interest.
Subcutaneous methotrexate an improvement, but biologics may be better


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Psoriasis vs depresion vs Artritis psoriatica

El hecho de tener paoriasis incrementa el riesgo de depresion y el hecho de tener ambas, incrementa el riesgo de padecer artritis psoriatica en un 37%.

Psoriasis and depression may pack a PsA punch

Patients with both psoriasis and major depressive disorder face an adjusted 37% greater risk of developing psoriatic arthritis (PsA) over a median follow-up of 5.1 years, a new study finds.

The findings don't definitively prove that depression plays a role in PsA. Still, "physicians managing patients with psoriasis must make efforts to identify and address depression, as this comorbidity may have a downstream impact," study coauthor Cheryl Barnabe, MD, MSc, said in an interview.

Researchers have linked psoriasis to a greater risk of depression. Another study found that patients with psoriasis had twice the odds of developing major depression, although there was no sign that increased severity boosted the risk (odds ratio, 2.09; 95% confidence interval, 1.41-3.11; P less than .001). Almost 17% of 351 patients with psoriasis showed signs of the condition (JAMA Dermatol. 2016 Jan;152[1]:73-9).

For the new study published by the Journal of Investigative Dermatology, researchers tracked 73,447 people in the United Kingdom with psoriasis through a primary care medical records database for up to 25 years. The study statistics come from the years 1987-2012, reported Ryan T. Lewinson of the Cumming School of Medicine, in Calgary, Alta., and his associates (J Invest Dermatol. 2017. doi: 10.1016/j.jid.2016.11.032).

The median age at psoriasis diagnosis was 49.5 years (range, 20-90 years) and the median follow-up time was 5.1 years; 2% of the patients developed PsA and 7% developed major depression.

Via an unadjusted model, those with signs of depression were 1.56 times more likely to develop PsA (hazard ratio; 95% CI, 1.28-1.90; P less than .0001). In a model adjusted for factors such as age, gender, and obesity status, the extra risk of PsA was 1.37 (HR; 95% CI, 1.05-1.80; = .021).

"The study draws into question the biological mechanisms by which depression increases the risk for developing psoriatic arthritis," said Dr. Barnabe, an associate professor with the departments of medicine and community health sciences at the University of Calgary and a rheumatologist with Alberta Health Services.

The study notes that depression is linked to poor diet and lack of exercise, factors that could contribute to PsA. The authors also point out that researchers have linked depression to inflammation, a crucial component of both psoriasis and PsA, although they note that the study doesn't examine systemic inflammation.

What's next? "Mental health in chronic inflammatory diseases is not well addressed at the present time, in our system anyway, and should be a prime area of focus," Dr. Barnabe noted. "Depression occurs at elevated rates in both psoriasis and psoriatic arthritis, and there is certainly a role for treatment to assist with disease management."

The study authors reported no specific study funding and no relevant financial disclosures.


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Thursday, March 16, 2017

Nueva crema tópica para psoriasis...

Tapinarof cream shows efficacy in treating plaque psoriasis

Tapinarof nonsteroidal anti-inflammatory topical cream, applied once or twice daily, showed efficacy in treating mild-to-moderate plaque psoriasis, according to late-breaking research presented at the American Academy of Dermatology Annual Meeting in Orlando, Florida.

Tomoko Maeda-Chubachi, MD, presented research on a randomized, evaluator-blinded study of 227 adults with psoriasis; about 80% of patients had mild-to-moderate plaque-type psoriasis. The study included a screening, 12 weeks of treatment with tapinarof topical cream (GSK2894512, GlaxoSmithKline). Tapinarof is as synthetic hydroxylated stilbene molecule that acts as an anti-inflammatory agent. No novel nonsteroidal topical therapies for psoriasis have been approved in more than 25 years, according to the researchers, with current topical options limited to corticosteroids or vitamin D analogs.

The primary endpoint was proportion of patients with physician global assessment (PGA) score of 0 or 1 (clear or almost clear) at week 12, with a minimum 2-grade improvement in 5-point PGA score from baseline to week 12. The secondary endpoint was proportion of patients achieving a 75% improvement in Psoriasis and Severity Index (PASI 75) score.

Patients were treated with 1% tapinarof cream once or twice daily, 0.5% tapinarof cream once or twice daily or vehicle once or twice daily.

There were 174 patients who completed the study.

The researchers found that 65% and 56% of patients in the twice-daily and once-daily tapinarof 1% groups, respectively, achieved the primary endpoint, as did 46% and 36% of patients in the twice-daily and once-daily tapinarof 0.5% groups, respectively. Among vehicle patients, 11% and 5% of the twice-daily and once-daily patients, respectively, reached the primary endpoint.

PASI 75 results were achieved by 65% and 56% of patients in the tapinarof 1% twice-daily and once-daily groups, respectively, and by 46% of patients in both the once-daily and twice-daily tapinarof 0.5% groups. In the vehicle group, 16% of the twice-daily group and 5% of the once-daily group achieved PASI 75.

Four weeks after discontinuation, efficacy was maintained.

Ten percent of patients in the tapinarof treatment groups and 1% of the vehicle treatment groups discontinued the study due to adverse events, with contact dermatitis being the most common adverse event leading to drug discontinuation.

Maeda-Chubachi and colleagues concluded that the 1% cream demonstrated higher efficacy than the 0.5% cream, and the 1% had quicker onset of action, with no difference between once- or twice-daily applications.

"Tapinarof cream 0.5% and 1% [once-daily] or [twice-daily] showed efficacy for plaque psoriasis in this study … [and] is generally safe and well tolerated," Maeda-Chubachi concluded. "Tapinarof cream could be an improved treatment option over existing therapy." – by Bruce Thiel

Reference:

Maeda-Chubachi T. F056 – Late-breaking Research Forum Clinical Trials. Presented at: American Academy of Dermatology Annual Meeting; March 3-7, Orlando.

Disclosure: Maeda-Chubachi reports being an employee of Glaxo-Smith-Kline, which sponsored the study.

Monday, March 13, 2017

Tratamiento de los Piojos

British Medical Journal recomienda:

Management approach

Treatment differs according to location and local guidelines should always be consulted.

Many products and techniques exist for the treatment of head lice, but the efficacy of many has not been proved. Also, products that worked well a decade ago are not now uniformly effective due to the development of resistance. [27] [38] [39] [40] 

The goals of treatment are eradication of the infestation in the individual patient and minimisation of spread to others. Because there is no mortality and minimal morbidity associated with infestation, it is important that treatments are safe. [41] Choice of product or technique will depend on a number of factors, including local resistance patterns (if known), parental preference, and ease of compliance. Healthcare professionals need to be knowledgeable about each treatment method, so it can be determined if a treatment failure represents head lice resistant to the product or non-compliance in usage of the product. [42] [43] 

General approach to treatment

Typical first-line treatment would be a pediculicide with a neurotoxic mode of action for at least 2 treatments (preferably day 0 and day 9). 

For patients who prefer not to use pediculicides with a neurotoxic mode of action, products with a physical mode of action or wet combing are reasonable alternatives. [38] [39] [44] 

Because head lice are very rarely spread via fomites, extensive hygiene practices are not necessary. More time spent on the infested child's head will yield better results. [8] [28] [29] 

Pediculicides

Recommendations for the management of head lice infestation are based on the best available evidence obtained from randomised controlled trials of head-louse treatment. However, great heterogeneity in trial methodologies currently exists, such as types of treatments compared, randomisation unit, blinding, treatment-administration site, diagnosis method and criteria, and primary outcome measures. An expert panel has recommended an optimal design to standardise head-louse treatment trials, but the procedure has only been rarely followed so far. [45] Interpretation of current recommendations should take this into account.

Dimeticones are generally considered a first-line treatment but permethrin 1%, as well as pyrethrins and organophosphate compounds (with or without piperonyl butoxide), may also be recommended depending on local guidelines. [46] Dimeticones have a physical mode of action.

There is widespread resistance to permethrin 1% or pyrethrins plus piperonyl butoxide products, especially where they have been widely used over many years. Resistance patterns are complex and are usually not known for the location in which the patient lives.[47] [48] [49] [50] [51] There are also safety concerns. [52] [53] 

Manufacturer's directions for use need to be followed closely to ensure a safe and effective outcome. Most compounds require a second treatment after 8-10 days to ensure elimination of all parasites. In this case, parents need to be informed and reassured that seeing live lice (nymphs) after the first treatment does not necessarily indicate treatment failure or resistance and they should continue to administer the additional treatments at the recommended intervals. 

Benzyl alcohol, ivermectin topical lotion, spinosad, or malathion are suitable alternative pediculicides if available. These products should only be used in patients ≥6 months of age (except malathion, which is recommended in children ≥2 years of age only). [8] Recommendations may differ in different locations and local guidelines should be consulted.

Lindane is an organochlorine that has important central nervous system toxicity in humans if used incorrectly. The US Food and Drug Administration (FDA) has issued a Public Health Advisory concerning the use of lindane, and its use has been banned in California. It has also been banned in Europe, and it is no longer recommend for the treatment of head lice. [54] 

Essential oils and other plant-derived compounds have been widely used in traditional medicine for the eradication of head lice, but due to the variability of their constitution in commercial products, the effects may not be reproducible. Although many plants naturally produce insecticides such as pyrethrins, these agents can produce toxic effects when used by humans. The safety and efficacy of herbal products are not regulated by the FDA or other agencies, and at the present time there is insufficient evidence to recommend their use. [11] [42] [55] [56] 

Mechanical removal

There are 2 main methods, nit picking and wet combing, and both can be used in any age group.

Nit picking (removal of eggs and hatched egg casing) is generally not recommended as a sole technique as lice and eggs can be difficult to find and remove. It may be used to augment the efficacy of treatment with permethrin and other compounds with a neurotoxic mode of action because these have no ovicidal activity. However, repeated use of a pediculicide may kill the newly hatched nymphs without having to remove all the eggs, so it is not absolutely necessary. If undertaken, a fine-toothed lice comb can aid in removal of the nits. A fine-toothed metal comb has been shown to be best.[57] One study found that eggs can be effectively removed from the hair with the use of a commercial conditioner. [58] 

Wet combing involves shampooing hair twice a week with ordinary shampoo, then vigorous combing out of wet hair with a special fine-toothed comb. [59] [60] [61] Success can be variable and depends largely on good technique. Combing of dry hair does not seem to have the same effect, and some have postulated that vigorous dry combing or brushing in closed quarters may actually spread lice by making them airborne via static electricity. [59] [62] 

Battery-operated louse combs or combs with oscillating teeth may not effectively reach to the scalp and do not kill or remove nits, so offer little advantage over a well-designed traditional louse comb.[63] Battery-operated combs have not been tested in younger children, and directions state that they should not be used in anyone with a known seizure disorder. Some products claim to loosen the attachment of eggs to the hair shaft; however, vinegar-based products have not been shown to have any clinical benefit. A variety of other substances, including acetone, bleach, vodka, and mechanical releasing oils, have proved to be ineffective in loosening nits from the hair shaft and present an unacceptable risk. [64] [65] 

Shaving the hair on the head, while effective, is not generally a socially accepted course of action and can cause emotional trauma.

A specialist device can be used to deliver controlled heated air to desiccate lice, but currently there is insufficient evidence to advocate its widespread use. [66] A regular blow-drier should not be used to accomplish the same result, because normal blow-driers can cause live lice to become airborne and spread to others in the vicinity. [66] Hot air guns should never be used.

Compounds with a physical mode of action

There are several products used, and choice depends primarily on location and the age of the patient.

Dimeticones belong to the group of synthetic silicone oils. The chain length and the solvent determine the viscosity of the product and other physical properties. [67] Dimeticones with low surface tension can perfectly coat microscopic surfaces. They have a purely physical mode of action and are not neurotoxic. If applied on a louse, they coat the cuticle of the insect, enter into the spiracles (tiny tracheae-like tubes leading into the louse body), and displace the air needed for breathing. They may also disrupt water management and cause subsequent osmotic stress and probable rupture of the gut. This causes death of the parasite with a delay of several hours. [68] [69] A 4% dimeticone solution in cyclomethicone showed an efficacy rate of between between 70% and 92%. [70] [71] [72] Another mixture of two dimeticones showed an efficacy rate of 97% in a population with a high intensity of infestation in Brazil. [73] In randomised control trials, dimeticones performed significantly better than permethrin 1% and malathion. [70] [73] [74] Some products also show high efficacy against eggs; however, there are no randomised controlled trials to support this. [75] [76] [77] Dimeticones are colorless and odorless and are considered nontoxic. Because of their mode of action, the development of resistance in lice is very unlikely. A systematic review concluded that dimeticones should be considered as the first-line treatment. [46] Dimeticones are not currently available in the US, but are used as a main treatment option in many countries in Europe, including the UK.

Petroleum jelly is thought to obstruct the respiratory spiracles of the adult louse and blocks holes in the operculum of the eggs. It can be used in any age group.

The Nuvo method uses Cetaphil Gentle Skin Cleanser applied to the hair and scalp, dried on with a blow-drier, then washed out 8 hours later, with the treatment repeated once a week for 3 weeks. One study reported a 96% cure rate but the study design was inappropriate (i.e., not controlled, randomised, or blinded). [78] [79] This method is only recommended in older children and adults.

Other occlusive substances have been suggested (e.g., mayonnaise, tub margarine, herbal oils, olive oil), but to date no information is available concerning efficacy. 

Specific treatment strategies

Infants aged <2 months

  • Rarely occurs in this age group. Mechanical removal can be safely used. If a patient in this age group has head lice, the infestation is likely to be minimal and individual head lice can easily be seen as the hair is very thin. It is better to remove these few head lice by hand instead of putting newborns at risk of adverse effects from other treatments.

Infants aged ≥2 months and <2 years

  • Dimeticones are the first-line agent in these patients. Permethrin 1%, or pyrethrins plus piperonyl butoxide, may also be considered.

  • Benzyl alcohol, ivermectin topical lotion, or spinosad are recommended in the US in areas with known resistance to first-line drugs. [8] Recommendations for alternative options in other countries may differ and depend on availability. Local guidelines should be consulted.

  • Patients who cannot or do not want to use pediculicides with a neurotoxic mode of action, or run the risk of inducing resistance, can use mechanical removal (i.e., nit picking or wet combing).

Children aged ≥2 years and adults

  • Dimeticones are the first-line agent in these patients. Permethrin 1%, or pyrethrins plus piperonyl butoxide, may also be considered.

  • Benzyl alcohol, ivermectin topical lotion, spinosad, or malathion are recommended in the US in areas with known resistance to first-line drugs. [8] Recommendations for alternative options in other countries may differ and depend on availability. Local guidelines should be consulted.

  • Malathion is an organophosphate (cholinesterase inhibitor). Due to reports of cross-resistance with pyrethroids and safety concerns (it is highly flammable), it is considered a third-line treatment. [80] [81] [82] [83] Although head lice resistant to malathion are common in the UK, where it has been used for decades, the preparation available in the US contains additional ingredients that themselves have a 50% cure rate, and this may delay development of resistance in the US.

  • Patients who cannot or do not want to use pediculicides with a neurotoxic mode of action, or run the risk of inducing resistance, may use mechanical removal (i.e., nit picking or wet combing).

Pregnant and lactating women

  • Most pediculicides can be used by pregnant women. However, all agents should be used with caution in lactation due to a lack of data.

  • For women who want an extra margin of safety, mechanical removal or compounds with a physical mode of action can be safely used instead.

Supportive measures

Supportive measures (e.g., cleaning hair items, bedding, or fabric items that have been in contact with an individual with an infestation) are still recommended in the US, but generally not in other countries.

Treatment of contacts

Household and other close contacts of infested individuals should be examined and treated if infested. Some experts recommend prophylactic treatment of household contacts, particularly siblings of the infested individual. Children should not be excluded or sent home early from school because of head lice. Parents of infested children (defined by visualisation of live lice) should be notified and informed that their child should be treated, ideally, before returning to school the next day. The presence of nits alone does not justify treatment. [2] [3] [4] 

Treatment of recurrence

Treatment of recurrence depends on whether the cause is due to resistance to a particular pediculicide, incorrect initial use of a pediculicide (or other method), or re-infestation from a contact. The cause is hard to prove, and the physician may have to make an educated guess after carefully questioning the patient about the steps that were followed when using pediculicide.

If resistance to a pediculicide with a neurotoxic mode of action is likely to be the cause, an alternative treatment with a physical mode of action is recommended. If incorrect use of a pediculicide (or other method) is suspected, it is important that instructions are made clear. In this case, re-infestation can be treated as for initial infestation.


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.